Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.
Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.
Pliant Therapeutics (Nasdaq: PLRX) will present new data on PLN-101095 at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, 2026.
The poster highlights FORTIFY, a Phase 1b indication expansion trial in ICI-refractory advanced or metastatic solid tumors.
Atisama Therapeutics, an Australian clinical-stage biotech, reported that its lead candidate RB042 has progressed into multiple ascending dose (MAD) cohorts in an ongoing Phase 1 trial in healthy volunteers and healthy smokers, with safety and tolerability demonstrated to date.
The company also appointed Dr. Bernard Coulie, President and CEO of Pliant Therapeutics (NASDAQ: PLRX), as Chair of its Board of Directors, adding extensive pulmonary disease and governance experience as RB042 advances through early clinical development.
Pliant Therapeutics (Nasdaq: PLRX) reported a Q1 2026 net loss of $20.0 million, down from $56.2 million, with research and development expenses cut to $13.6 million and general and administrative expenses to $8.2 million. Cash and investments totaled $172.4 million, expected to fund operations into the second half of 2028.
The first participant was dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 in ICI-refractory tumors. Updated Phase 1 data showed one confirmed complete response and two confirmed partial responses in combination with pembrolizumab, with PLN-101095 generally well tolerated.
Pliant Therapeutics (Nasdaq: PLRX) will participate in the RBC Capital Markets Global Healthcare Conference on May 19, 2026. Pliant’s CEO Bernard Coulie, M.D., Ph.D., and CFO Keith Cummings, M.D., will take part in a fireside chat at 11:30 a.m. ET. A live webcast will be available via the company’s Investor Relations Events & Presentation page, and a replay will be archived for 30 days following the event.
Pliant Therapeutics (Nasdaq: PLRX) announced dosing of the first participant in FORTIFY, a Phase 1b open-label indication expansion trial of oral PLN-101095 plus pembrolizumab in ICI-refractory advanced or metastatic solid tumors.
The trial enrolls three expansion cohorts (NSCLC, clear cell RCC, high tumor mutational burden tumors). PLN-101095 is dosed 1,000 mg twice daily for 14 days as monotherapy before adding pembrolizumab. Enrollment is underway; interim data are expected in 2027.
Pliant Therapeutics (Nasdaq: PLRX) presented updated Phase 1a/1b data for PLN-101095 plus pembrolizumab at AACR 2026, with data cutoff Feb 27, 2026. In three confirmed responders median time on treatment was 19 months and average baseline tumor reduction was 89%. PLN-101095 at doses ≥1000 mg BID achieved sustained IC90 coverage; few discontinuations (n=2) were reported and rash was the most common TRAE (all Grade 1–2). A Phase 1b indication expansion is underway with interim data expected in 2027.
Pliant Therapeutics (NASDAQ: PLRX) announced an oral presentation of Phase 1 data for PLN-101095 at the AACR Annual Meeting, April 17-22, 2026, in San Diego.
The Clinical Trials Mini Symposium presentation on April 18, 2026 will report first-in-human results for PLN-101095 as monotherapy and with pembrolizumab in ICI-refractory solid tumors.
Pliant Therapeutics (Nasdaq: PLRX) reported Phase 1 data for lead oncology candidate PLN-101095 showing deep, durable responses in ICI‑refractory solid tumors and announced an accelerated development plan with a Phase 1b indication expansion trial.
Key items: four responders in 10 secondary ICI‑refractory patients, initiation of NSCLC/clear cell RCC/high‑TMB cohorts with enrollment expected Q2 2026 and interim data in 2027, published INTEGRIS‑PSC results, new COO appointment, and $192.4M cash runway into H2 2028.
Pliant Therapeutics (Nasdaq: PLRX) will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026. A fireside chat featuring Bernard Coulie, M.D., Ph.D., CEO, and Keith Cummings, M.D., CFO, is scheduled for Feb 25, 2026 at 2:40 p.m. ET.
According to the company, the live webcast will be accessible via Pliant’s Investor Relations events page, and a replay will be archived on the Pliant website for 30 days after the event.
Pliant Therapeutics (NASDAQ: PLRX) reported interim Phase 1 dose-escalation data for oral PLN-101095 combined with pembrolizumab in ICI-refractory advanced/metastatic solid tumors dated Dec 4, 2025. In the three highest dose cohorts, 4 responders were observed among 10 secondary ICI-refractory patients (1 confirmed CR, 2 confirmed PR, 1 unconfirmed PR). Median time on treatment for responders was 15 months as of Nov 30, 2025. 60% of secondary refractory patients showed stable disease or tumor reduction. Responders had 4- to 13-fold increases in plasma IFN-γ after 14-day PLN-101095 monotherapy. Drug was generally well tolerated with 2 discontinuations. Company plans a Phase 1b expansion in 2026 and says cash supports operations through 2028.